Jeito Capital
Paris-based life-sciences venture capital firm founded in 2018 by Rafaele Tordjman, MD PhD, ex-Sofinnova Managing Partner, dedicated to financing breakthrough biopharma innovation for patient benefit across Europe and North America. Two funds: Jeito I closed at EUR 534M in July 2021 and Jeito II at EUR 1.23bn in April 2026, the largest-ever independent biopharma-focused European fund, for around EUR 1.73bn total AUM. The 22-company portfolio counts three trade-sale exits: Neogene Therapeutics to AstraZeneca (USD 320M total, 2023), HI-Bio to Biogen (USD 1.8bn total, July 2024) and EyeBio to Merck (USD 3bn total, late 2024), plus the Nasdaq IPO of Odyssey Therapeutics in May 2026 (ODTX, USD 304M raised).
Jeito Capital is a Paris venture capital firm with €1.6B AUM, 19 active companies and 6 exits.
- ·6 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 6 realized deals: 3 years.
- ·Top sector focus: Biotech (100% of portfolio).
- ·Fund cadence: ~5Y between vintages · last raise 2026.
Geography breakdown
9 geographiesKey facts
Recent exits
Jeito Capital took Odyssey Therapeutics public in 2026 after 1 year.
Jeito Capital exited Precirix in 2026 after 4 years.
Jeito Capital sold EyeBio to Merck in 2024 after 2 years.
Jeito Capital sold HI-Bio to Biogen in 2024 after 3 years.
Coverage notes
2 funds tracked, 25 portfolio companies (19 active · 6 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Jeito Capital has raised, with its portfolio companies. Hand-checked from public filings.
Jeito IIVC2026€1.0B9 assets1 exitsVC2026 · 0yr€1.0B91
Unrealized
9 held| Company | Entry |
|---|---|
| Adcendo Biotech · Denmark | 2026 |
| Alveus Therapeutics Biotech · US | 2026 |
| Augustine Therapeutics Biotech · Belgium | 2025 |
| Aviceda Therapeutics Biotech · US | 2024 |
| Azafaros Biotech · Netherlands | 2025 |
| Bionyra Pharma Biotech · France | 2026 |
| Callio Therapeutics Biotech · US | 2025 |
| ReproNovo Biotech · Switzerland | 2024 |
| XyloCor Therapeutics Biotech · US | 2024 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Odyssey Therapeutics Biotech · US | 2025 | 2026 | IPO | – | – |
Jeito IVC2021€534M10 assets5 exitsVC2021 · 5yr€534M105
Unrealized
10 held| Company | Entry |
|---|---|
| Advesya Biotech · Spain | 2022 |
| Alentis Therapeutics Biotech · Switzerland | 2021 |
| CatalYm Biotech · Germany | 2022 |
| CDR-Life Biotech · Switzerland | 2022 |
| Corteria Pharmaceuticals Biotech · France | 2023 |
| NMD Pharma Biotech · Denmark | 2022 |
| Noema Pharma Biotech · Switzerland | 2023 |
| Pulmocide Biotech · UK | 2021 |
| Quell Therapeutics Biotech · UK | 2021 |
| SparingVision Biotech · France | 2020 |
Realized
5 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| EyeBio Biotech · US | 2022 | 2024 | Trade Sale | Merck | – |
| HI-Bio Biotech · US | 2021 | 2024 | Trade Sale | Biogen | – |
| InnoSkel Biotech · France | 2020 | 2024 | – | – | – |
| Neogene Therapeutics Biotech · Netherlands | 2020 | 2023 | Trade Sale | AstraZeneca | – |
| Precirix Biotech · Belgium | 2022 | 2026 | – | – | – |
About Jeito Capital
Jeito Capital is a French private equity firm with €534 million of assets under management as of December 2024, headquartered in Paris. Founded in 2018, the firm focuses on buyout and growth equity investments in European mid-cap businesses across healthcare, deploying capital from successive flagship funds with institutional limited partner support.
Investment thesis
Jeito Capital deploys buyout capital into European mid-cap and small-cap businesses across healthcare, targeting majority equity positions in profitable companies with clear value-creation runways. Investment focus emphasises operational improvement, selective bolt-on M&A acceleration and selective international expansion across France and selectively across Europe, with capital deployed from successive flagship funds backed by institutional limited partners.
Recent activity
Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 2 fund vehicles, 19 active portfolio companies and 0 realised exits across the strategy's history.
Frequently asked questions
- What investment strategy does Jeito Capital focus on?
- Jeito Capital focuses on VC strategies in the private equity space.
- How many portfolio companies does Jeito Capital have?
- Jeito Capital has 19 active portfolio companies and 6 completed exits and 2 funds tracked on GP Intel.
- Where is Jeito Capital headquartered?
- Jeito Capital is headquartered in Paris, France.
- What is Jeito Capital's assets under management?
- Jeito Capital manages approximately €1.6B in assets under management.
- When was Jeito Capital founded?
- Jeito Capital was founded in 2018.
- What sectors does Jeito Capital invest in?
- Jeito Capital invests across Healthcare.
- What are Jeito Capital's recent exits?
- Recent realized exits by Jeito Capital include: EyeBio (2024) to Merck; HI-Bio (2024) to Biogen; Neogene Therapeutics (2023) to AstraZeneca.
Similar firms
Other private equity firms tracked on GP Intel.
France·€1.6B
France·€1.6B
France·€1.7B
France·€1.5B
France·€1.5B
France·€1.8B
France·€1.3B
France·€2.0B
France·€2.0B
France·€1.2B
France·€2.0B
France·€1.1B